IHS Announces CE Mark Certification for Proprietary Syringe Infusion System
Innovative Health Sciences, LLC (“IHS” or the “Company”) announced today that they have received ISO 13485 quality management system and CE mark certification for the Insignis™ Syringe Infusion System. The CE mark, abbreviated for European Conformity ("Conformité Européene"), enables IHS to sell the system throughout the European Union.
The Insignis™ Syringe Infusion System is the first combination of intravenous and subcutaneous non-electric infusion pump created for use with a selectable rate flow controller, the IV Controller and the OneSett™.
The transformative Insignis™ System for intravenous administration answers the world-wide need for a portable, non-electric, versatile, cost-effective, and intuitive infusion pump to accurately deliver medications from KVO up to 250ml/hr with a direct reading selectable rate flow controller.
For subcutaneous applications, the OneSett™ consists of a selectable rate flow controller attached directly to a subcutaneous needle set (1-4 leg configuration offering), which enables the user to select the flow rate (from 10ml – 60ml) with the turn of a dial. The flow rate indicated on the dial is delivered to each needle site – no calculation required!
The Insignis™ syringe pump is much less costly, offered at 139 Euro, and when considering the cost of the separate pieces of the ancillary supplies (needle sets, flow control tubings, and flow controller), the OneSett™ is also lower cost per infusion – even before considering the savings incurred from fewer stocking parts.
The IHS infusion system addresses nearly every infusion therapy need and can support intermittent, “pause” dosing, ideal for lengthy low-volume hospital infusions. “The IHS system represents a paradigm shift in simplicity, excellence, cost effectiveness, usability and patient-centered design,” says Andrew Sealfon, IHS founder, Chairman, and CTO.
Sealfon is a forty-year investor, innovator, and executive of the medical device industry. Inventor and founder of Repro-Med Systems, Inc. (KORU Medical Systems), Sealfon served as its President, Chairman of the Board, and Chief Executive Officer from September 1982 until his termination (July 25, 2018).
About Innovative Health Sciences
New York-based Innovative Health Sciences, LLC provides innovative solutions to the infusion healthcare market. IHS’ approach is patient-centric and future-oriented; our goal is to provide the highest quality of life by empowering the patient to take control of their infusion.
The statements contained herein are not guaranteed of future performance and undue reliance should not be placed on them. Such Forward-Looking Statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied. These statements are based on management’s beliefs and theory. The Company undertakes no obligation to update Forward-Looking Statements if circumstances or management’s estimates or opinions should change, except as required by applicable securities laws.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MOODY’S-ESG3.8.2021 10:16:06 CEST | Press release
Moody’s ESG Solutions Launches Solution to Help Investors Assess Alignment With UN Global Compact
BOEHRINGER-INGELHEIM3.8.2021 10:02:05 CEST | Press release
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
SES-NETWORKS/ORANGE3.8.2021 08:52:03 CEST | Press release
SES Networks Expands Partnership With Orange to Enhance Maritime Services
GOPHER-INVESTMENTS3.8.2021 08:02:12 CEST | Press release
Gopher Response to Statement by Playtech, Related Clarifications and Reasons Why Shareholders Should VOTE AGAINST the Consortium Offer
RELIEF3.8.2021 07:05:13 CEST | Press release
Relief Announces Receipt of U.S. FDA Orphan Drug Designation for the use of RLF-100 (aviptadil) in the Treatment of Sarcoidosis
P.I.-WORKS3.8.2021 07:02:06 CEST | Press release
Smart Engages P.I. Works for Expanded Network Automation Solution
CA-PERSONALIS2.8.2021 22:07:05 CEST | Press release
Personalis, Inc. Publishes New Data Demonstrating a Novel Composite Biomarker NEOPS™ for Predicting Response to Cancer Immunotherapy in Late-Stage Melanoma Patients
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom